FY2027 ICD-10-CM reference

E70.321: Tyrosinase positive oculocutaneous albinism

By the HCC Buddy Coding Team

The official ICD-10-CM descriptor is Tyrosinase positive oculocutaneous albinism. The FY2027 annual edition starts October 1, 2026. Check the edition that applies to the encounter or inpatient discharge, including any April update.

Billable code. Verified against the official FY2027 order file.

CMS-HCC V28

No V28 HCC for 2026 dates of service (CMS 2027 Initial ICD-10-CM Mappings)

CMS-HCC V24

Not used for payment year 2027 Medicare Advantage payment

ESRD

HCC 23: Other Significant Endocrine and Metabolic Disorders

CMS lists the same category for every age band in its model mapping

No RAF is shown: it depends on the member. Mapping: PY2026 CMS mapping; CMS 2027 initial file unchanged.

PACE

Source verification pending

RxHCC

HCC 43: Pituitary, Adrenal Gland, and Other Endocrine and Metabolic Disorders

Coefficient pending: payment year 2027 coefficients for this model are not yet verified, so no RAF is shown. Mapping: PY2026 CMS mapping; CMS 2027 initial file unchanged.

HHS-HCC

HCC 28: HHS-HCC 28

This code has a CMS age requirement: applies when age < 21

No RAF is shown: it depends on the member. Mapping: HHS-HCC 2026 benefit year.

FY2027 Tabular instructions

Instructions below include applicable chapter, section and parent-code notes. Each note identifies where it appears in the official source.

Instructional note

All neoplasms, whether functionally active or not, are classified in Chapter 2. Appropriate codes in this chapter (i.e. E05.8, E07.0, E16-E31, E34.-) may be used as additional codes to indicate either functional activity by neoplasms and ectopic endocrine tissue or hyperfunction and hypofunction of endocrine glands associated with neoplasms and other conditions classified elsewhere.

Source: E00-E89 (chapter, inherited).

Excludes1

transitory endocrine and metabolic disorders specific to newborn (P70-P74)

Source: E00-E89 (chapter, inherited).